{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:39:34Z","timestamp":1792528774127,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"DOI":"10.1007\/s11523-026-01237-w","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:48:38Z","timestamp":1792468118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct05224141","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-7464","authenticated-orcid":false,"given":"Jacob","family":"Sands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Shentzer Kutiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Casarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin Yup","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0141owczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himani","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"El-Osta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"5","key":"1237_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/onco.13752","volume":"26","author":"L Mathieu","year":"2021","unstructured":"Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433\u20138. https:\/\/doi.org\/10.1002\/onco.13752.","journal-title":"Oncologist"},{"issue":"6","key":"1237_CR2","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3322\/caac.21785","volume":"73","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73(6):620\u201352. https:\/\/doi.org\/10.3322\/caac.21785.","journal-title":"CA Cancer J Clin"},{"key":"1237_CR3","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guidelines). Small Cell Lung Cancer. Version 4.2025. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462. Accessed 9 Apr 2025."},{"issue":"23","key":"1237_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"10212","key":"1237_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"issue":"21","key":"1237_CR6","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Cs\u0151szi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1237_CR7","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/eji.201041136","volume":"41","author":"SD Levin","year":"2011","unstructured":"Levin SD, Taft DW, Brandt CS, Bucher C, Howard ED, Chadwick EM, et al. VSTM3 is a member of the CD28 family and an important modulator of T-cell function. Eur J Immunol. 2011;41(4):902\u201315. https:\/\/doi.org\/10.1002\/eji.201041136.","journal-title":"Eur J Immunol"},{"issue":"2","key":"1237_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. https:\/\/doi.org\/10.1136\/jitc-2020-000957.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1237_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00543-z","volume":"12","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu X, Gu Z, Jiang Z, Zhao S, Song Y, et al. Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 2024;12(1):7. https:\/\/doi.org\/10.1186\/s40364-023-00543-z.","journal-title":"Biomark Res"},{"issue":"6","key":"1237_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. 2014;26(6):923\u201337. https:\/\/doi.org\/10.1016\/j.ccell.2014.10.018.","journal-title":"Cancer Cell"},{"issue":"10","key":"1237_CR11","doi-asserted-by":"publisher","first-page":"S974","DOI":"10.1016\/j.jtho.2018.08.1836","volume":"13","author":"H Yu","year":"2018","unstructured":"Yu H, Koczara C, Lohinai Z, Badzio A, Czapiewski P, D\u00f6me B, et al. P3.12-13 expression of the immune checkpoint axis-PVR\/TIGIT in small cell lung cancer. J Thorac Oncol. 2018;13(10):S974\u20135. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.1836.","journal-title":"J Thorac Oncol"},{"issue":"16 Suppl.","key":"1237_CR12","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1158\/1538-7445.AM2020-5614","volume":"80","author":"DX He","year":"2020","unstructured":"He DX, Nie C, Zheng L, Sun R, Zhang M, An AX, et al. Abstract 5614: combination of anti-TIGIT and anti-PD-1 antibodies enhance antitumor response in a PD-1\/TIGIT double HuGEMM\u2122 model engrafted with mouse syngeneic tumors. Cancer Res. 2020;80(16 Suppl.):5614. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-5614.","journal-title":"Cancer Res"},{"issue":"8","key":"1237_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769. https:\/\/doi.org\/10.1080\/2162402X.2018.1466769.","journal-title":"Oncoimmunology"},{"issue":"12","key":"1237_CR14","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","volume":"70","author":"K Hansen","year":"2021","unstructured":"Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, et al. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021;70(12):3525\u201340. https:\/\/doi.org\/10.1007\/s00262-021-02921-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"1237_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","volume":"33","author":"J Niu","year":"2022","unstructured":"Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer. Ann Oncol. 2022;33(2):169\u201380. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.002.","journal-title":"Ann Oncol"},{"key":"1237_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19466315.2013.807748","volume":"5","author":"W Maurer","year":"2013","unstructured":"Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. Stat Biopharm Res. 2013;5:311\u201320. https:\/\/doi.org\/10.1080\/19466315.2013.807748.","journal-title":"Stat Biopharm Res"},{"issue":"3","key":"1237_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1200\/JCO.23.01363","volume":"42","author":"CM Rudin","year":"2024","unstructured":"Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, et al. SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2024;42(3):324\u201335. https:\/\/doi.org\/10.1200\/JCO.23.01363.","journal-title":"J Clin Oncol"},{"issue":"7 Suppl.","key":"1237_CR18","doi-asserted-by":"publisher","first-page":"CT255","DOI":"10.1158\/1538-7445.AM2024-CT255","volume":"84","author":"Y Gong","year":"2024","unstructured":"Gong Y, Pang Q, Yu R, Zhu Z, Huang J, Cheng Y, et al. Abstract CT255: AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC). Cancer Res. 2024;84(7 Suppl.):CT255. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT255.","journal-title":"Cancer Res"},{"key":"1237_CR19","unstructured":"Keytruda (pembrolizumab). Full prescribing information. Rahway: Merck Sharp & Dohme LLC; 2024."},{"issue":"8","key":"1237_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03734-1","volume":"73","author":"Y Chen","year":"2024","unstructured":"Chen Y, Han H, Cheng J, Cheng Q, Zhu S, Zhan P, et al. Efficacy and safety of anti-PD-1\/PD-L1-based dual immunotherapies versus PD-1\/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Cancer Immunol Immunother. 2024;73(8):155. https:\/\/doi.org\/10.1007\/s00262-024-03734-1.","journal-title":"Cancer Immunol Immunother"},{"key":"1237_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146905","volume":"13","author":"M Alifu","year":"2023","unstructured":"Alifu M, Tao M, Chen X, Chen J, Tang K, Tang Y. Checkpoint inhibitors as dual immunotherapy in advanced non-small cell lung cancer: a meta-analysis. Front Oncol. 2023;13:1146905. https:\/\/doi.org\/10.3389\/fonc.2023.1146905.","journal-title":"Front Oncol"},{"issue":"1","key":"1237_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/1759-7714.15178","volume":"15","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Liu J, Ma J, Kang R, Liu Z, Yu J. Advances in new targets for immunotherapy of small cell lung cancer. Thorac Cancer. 2024;15(1):3\u201314. https:\/\/doi.org\/10.1111\/1759-7714.15178.","journal-title":"Thorac Cancer"},{"issue":"4","key":"1237_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/life13041050","volume":"13","author":"C Pescia","year":"2023","unstructured":"Pescia C, Pini G, Olmeda E, Ferrero S, Lopez G. TIGIT in lung cancer: potential theranostic implications. Life (Basel). 2023;13(4):1050. https:\/\/doi.org\/10.3390\/life13041050.","journal-title":"Life (Basel)"},{"issue":"3","key":"1237_CR24","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.3892\/ol.2019.9910","volume":"17","author":"Y Xu","year":"2019","unstructured":"Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett. 2019;17(3):2960\u20138. https:\/\/doi.org\/10.3892\/ol.2019.9910.","journal-title":"Oncol Lett"},{"issue":"3","key":"1237_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39(3):346-60.e347. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014.","journal-title":"Cancer Cell"},{"key":"1237_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241249627","volume":"16","author":"R Khan","year":"2024","unstructured":"Khan R, Coleman N. Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer. Ther Adv Med Oncol. 2024;16:17588359241249627. https:\/\/doi.org\/10.1177\/17588359241249627.","journal-title":"Ther Adv Med Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01237-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01237-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01237-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:03:00Z","timestamp":1792526580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01237-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":26,"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01237-w","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jacob Sands: consulting for AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Curadev, Daiichi-Sankyo, Fosun, Gilead, Jazz Pharmaceuticals, Lilly, Mariana Oncology, Medtronic, Merck, Novartis, Pfizer, Sanofi, and Summit Therapeutics; and research funding from Harpoon and Novartis. Shun Lu: consulting or advisory role for AstraZeneca, Boehringer Ingelheim, GenomiCare, Hutchison MediPharma, InventisBio Co. Ltd, Menarini, Pfizer, Roche, Simcere, Yuhan, and Zai Lab; speakers bureau for AstraZeneca, Hansoh Pharma, Hengrui Therapeutics, and Roche; research funding for AstraZeneca (institution), BeiGene (institution), BMS (institution), Hansoh (institution), Hengrui Therapeutics (institution), Hutchison MediPharma (institution), Lilly Suzhou Pharmaceutical Co. (institution), and Roche (institution). Joachim G. Aerts: personal fees from AstraZeneca, Amphera, Eli Lilly, MSD, and Nutricia and a stock owner in Amphera. Martin Reck: personal fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, BeiGene, Daiichi-Sankyo, GSK, Eli Lilly, Merck Serono, Mirati, MSD, Novartis, Regeneron, Roche, and Pfizer. Alejandro Navarro: consulting or advisory role for Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Daiichi Sankyo, BeiGene, Regeneron, Roche, MSD, Janssen, Takeda, Pfizer, Hengenix Biotech, Eczacibasi, Oryzon Genomics, and Tecnofarma. Talia Shentzer Kutiel: no conflicts of interest declared. Nir Peled: received grants, personal fees, and\/or honoraria as an advisor from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, NovellusDx, Foundation Medicine, and Guardant360. Ignacio Casarini: received speaker honoraria from AstraZeneca; serves as a clinical trial investigator in studies sponsored by multiple pharmaceutical companies; and has attended scientific meetings with travel support from various industry sponsors. Samuel J. Kerr: received research funding (to institution) from BMS\/Sanofi, Genentech, Merck, and Loxo\/Lilly. Toshiaki Takahashi: received honoraria for lectures from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd, MSD K.K., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd, Amgen K.K., BMS Japan, Taiho Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd.; grants from AstraZeneca K.K., MSD K.K., Janssen Pharmaceutical K.K., Amgen K.K., and AnHeart Therapeutics Inc. Shin Yup Lee reports research support through the institution for conducting clinical trials sponsored by Amgen, Bristol Myers Squibb, Eli Lilly, MSD, Roche, Merck, BeiGene, Pfizer, GSK, AstraZeneca, Yuhan, Mirati Therapeutics, and Taiho Pharmaceutical; consulting fees from Merck, BeOne Medicines, Amgen, Bayer, AstraZeneca, MSD, Pfizer, Takeda, Yuhan, and Boryung; and honoraria from AstraZeneca.\u00a0Ahmet Bilici, Ying Cheng, and\u00a0Mengzhao Wang have no conflicts of interest that are directly relevant to the content of this article. Anna \u0141owczak: research support or grants from Innate Pharma, Daiichi Sankyo, PharmaMar, Pfizer, Genmab, GSK, PSI Pharma, BMS, MSD, and AstraZeneca and a consultant for PharmaMar. Julien Mazieres: personal fees from Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Pfizer, Jiangsu Hengruii, Blueprint, Daiichi, Novartis, and Amgen; and grants from Roche, AstraZeneca, Pierre Fabre, and BMS. Haixia Hu: employee of MSD (China) Co., Ltd., Beijing, China and may own stock in Merck & Co., Inc., Rahway, NJ, USA. Jianyu Wu, Himani Aggarwal, and Hazem El-Osta: employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may own stock in Merck & Co., Inc., Rahway, NJ, USA. Himani Aggarwal also owns stock in Eli Lilly. Luis Paz-Ares: consulting fees from Lilly, MSD, Roche, PharmaMar, Merck KGaA (Darmstadt, Germany), AstraZeneca, Novartis, Pfizer, Sanofi, Bayer, BMS, Mirati, GSK, Janssen, Takeda, Regeneron, Sanofi, Gilead, Roche, AbbVie, and Daiichi Sankyo; grants or contracts from MSD, AstraZeneca, BMS, and Pfizer; and honoraria for lectures\/speakers bureau from AstraZeneca, Janssen, Merck Serono, Mirati, and Sanofi.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with principles of Good Clinical Practice and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. The study protocol and informed consent form were reviewed and approved by an institutional review board\/independent ethics committee before being implemented at each study site.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Participants provided written informed consent.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company\u2019s clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data-sharing website (available at:\n                      \n                      ) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the USA and European Union or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JS had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conceptualization: HE-O, JS, MR, SL. Data curation: AB, AN, A\u0141, HE-O, IC, JS, JGA, JM, LP-A, MW, NP, SJK, SYL, SL, TT, YC. Formal analysis: HH, HE-O, IC, JS, JW, JM, MR, SL, TSK, YC. Investigation: AB, AN, A\u0141, HH, HE-O, HA, JS, JW, JGA, JM, LP-A, MR, NP, SL. Writing (original draft): HE-O, JS. Writing (reviewing and editing): all authors. Resources: A\u0141, JM, LP-A, MR, SYL, SL. Final approval of the manuscript: all authors.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}